Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depakote for Disruptive Behavior Disorder
NCT00218114Phase 3Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Feb 2000
- Primary completion
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Disruptive behavior disorders (DBD) comparing Divalproex Sodium with Placebo (2 arms). Primary endpoint: Symptoms of disruptive behavior disorder at 6 weeks. Started Feb 2000; status: completed.
02
Drugs
divalproex sodium
03
Conditions
Disruptive behavior disorders (DBD)
Beyond the preview
Go deeper on NCT00218114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00218114.